Background. Clinical practice guidelines should be based on the best available evidence. However, this evidence is often incomplete, controversial, or lacking. Other considerations beyond the evidence are therefore needed to be able to formulate specific and applicable recommendations for clinical practice.
In the last few decades, the number of published clinical practice guidelines has grown exponentially. An important aim of guidelines is to provide clinicians with information that helps them in making clinical decisions. Most professionals also use guidelines to maintain and improve the quality of health care services. To ensure high quality, the guidelines should be based on the best available scientific evidence. However, the evidence is often incomplete and controversial, so the transformation of evidence into recommendations is not straightforward [1, 2] . The health benefits, side effects, and risks of different options for managing the disease or condition should also be considered. This step can be defined as 'considered judgement' [3, 4] , which is an extra dimension beyond the available evidence in formulating recommendations in guidelines. A valid tool for a systematic approach to this part of the guideline-development process is not available yet, in contrast to the numerous instruments that can be used for the critical appraisal and grading of scientific literature. In this article, we are introducing a systematic approach to identify items that should be included in the process of considered judgement to formulate recommendations in clinical guidelines.
Methods

Design and validity testing of the framework
This study was conducted from June 2003 until February 2004. On the basis of a literature review [5] and an existing list used in guideline development by the Dutch Institute for Healthcare Improvement CBO, we considered 49 items grouped into 10 potentially relevant domains: (i) clinical relevance, (ii) safety, (iii) patient's perspective, (iv) availability of resources, (v) health care costs, (vi) organization of care, (vii) professional's perspective, (viii) legal consequences, (ix) possible conflicts of interest by the industry, and (x) other 'considered judgements'.
A policy, Delphi procedure, was used to test the content and concurrent validity of this framework [6] [7] [8] [9] [10] [11] . A panel of experts involved in evidence-based guideline development was recruited from the Dutch network of guideline organizations [12] . Aims of this network are to improve the methodology of guideline development and to avoid duplication of efforts. We asked the representatives of the member organizations to participate in our study at the regular meeting of the network. As all representatives were experienced in guideline development, we consider them as experts.
In the first Delphi round, each panel expert was asked to independently rate the relevance of the items on a 4-point Likert scale (ranging from 'very important' to 'not important') and to comment on the individual domains and items (in a comment box adjacent to the items). The participants were also asked to comment on the list in general and to suggest new domains and/or items.
The panel responses were aggregated, tabulated, summarized, and returned to the participants in the second Delphi round. The domains and items were the same as in the first round. The participants rated the relevance of each item again and commented on the feedback. In addition, the participants were asked to decide whether to keep or remove the item from the list. The participants were reminded by electronic mail over a period of 3-8 weeks to send back their list (and questionnaire).
Analysis
The mean score and standard deviation (SD) were calculated for each item. Standardized domain scores were calculated by adding up the scores from all the experts and standardizing them as a percentage of the possible maximum score [10, 13, 14] .
The final list was composed of items that at least 60% of the experts wanted to have included [6, 7] . In contrast to the threshold of 70-75% that is recommended in the literature, we used a lower threshold of 60% because of the explorative nature of the study [6] .
The overall agreement of the first and second Delphi rounds was calculated as well as the correlation between the decision to accept an item as 'relevant to be considered' for formulating recommendations and the item score (= equivalence reliability). The Spearson's product correlation coefficient (r s ) was used, with 0.8 as the limiting value to demonstrate a significant correlation [15, 16] .
Results
Participants
Twenty-eight experts from 16 different professional organizations in guideline development agreed to participate in the first Delphi round, and 21 of them participated in the second round. The lower response in the second round was partly because of lack of time (n = 3); four participants did not respond at all.
First Delphi round
The initial list generated significant agreement on the domains 'clinical relevance', 'safety', 'availability of resources', 'patient's perspective', and 'legal consequences'. Eight of the 12 items in the domain 'organization of care' had an average score lower than 3.0 (range 2.2-2.8). A few participants (n = 10) noted that these items are part of the implementation phase. Some of the participants (n = 7) felt that the domain 'possible conflicts of interest by the industry' could be a 'threat' in formulating a recommendation, but this had the lowest mean (2.0) of all 10 domains. Some participants (n = 10) had difficulties with certain items in the domain 'health care costs'.
Second Delphi round
The domains and their items and how they were scored by the Delphi panel are summarized in the Appendix. In response to the results of the two Delphi sessions, the number of domains was reduced to nine, and a new item 'addressing ethical issues' was included. Following comments from the first round, some items in the domains 'organization of care' and 'clinical relevance' were reformulated, and more explanation was added to the items described in the domain 'health care costs'. A comment from the participants was that a health technology assessment expert should be represented in each working group because of the limited knowledge of economic studies ('health technology assessment studies') and cost analysis.
The final checklist for 'considered judgement' contained 37 items grouped into nine domains. The items in the domains 'clinical relevance', 'safety', and 'availability of resources' had consensus scores ranging from 80 to 95%. The domain 'safety' had the highest score.
Six of the 12 items in the domain 'organization of care' were excluded because of a lack of consensus. A possible explanation for this, as several participants stated, is that these items belong in the implementation phase after the guideline was finalized.
Four of the nine items in the domain 'professional's perspective' had a consensus score lower than 60% and were excluded.
The impact of the legislation and rules on the professional and on the intervention when formulating a recommendation had a consensus score of 70-75%. 'The legal consequences when a guideline is not followed' was excluded (consensus 55%).
The domain 'possible conflicts of interest by industry' had a low consensus score (25%) and was therefore excluded.
The criteria of 'trustworthiness' that underwrites the reliability and validity of this research are all taken into account [7] . The acceptance of an item ('yes' option) was related to a high mean score on the 4-point Likert scale for that item (second Delphi round versus 'yes' S p = 0.74, P < 0.001). The final checklist 'considered judgement' contained 37 items grouped into nine domains.
Discussion
We designed a framework in this study to structure the process of 'considered judgement' to formulate the recommendations into guideline development in the Netherlands. This was validated in two Delphi rounds by a panel of experts.
High scoring domains were 'clinical relevance', 'safety', and 'availability of resources'. The most commonly reported problem was the interpretation of several items in the initial list. After providing a more detailed (or improved) explanation of the items, the participants made only minor comments on the second Delphi list.
Using a threshold of 60%, we achieved consensus on 9 domains and 37 items. This threshold was set because of the explorative character of the study. A threshold of 70-75% is often recommended in the literature [6] . If this higher threshold had been used, there would be 29 items in the final checklist. Further testing of the usefulness and applicability of the items in the list is needed. This may further reduce the number of items.
Guidelines should be based on the integration of the best available evidence, clinical expertise, and patients' values and needs [17] . Almost all the participants in this study acknowledged the relevance of the concept of 'considered judgement' in guideline development, including patients' values and perspectives. Patient participation during guideline development may help to remind the guideline-working group not to focus exclusively on the scientific evidence [3] [4] [5] . Guidelines should also include information about possible side effects and the risks of the procedures and interventions that are recommended.
Organizational barriers and the impact on health care costs should also be considered in the development of guidelines [18, 19] . In addition, effective guidelines include recommendations that are compatible with existing norms and values in daily practice and are feasible and applicable on a day-to-day basis. In practice, the need to acquire new knowledge or skills and changes in the organization and in existing routines may hamper the application of the guideline [14, 20] . Using the list of 'considered judgements', these aspects can be systematically considered at all phases of the guideline-development process [3, 18] .
Owing to a lack of consensus, the domain 'possible conflicts of interest by industry' was excluded. It has been reported that contacts between physicians and the pharmaceutical industry are increasing [21] . Guidelines may also be influenced by industry through industrial funding of trials and by working group members having conflicts of interest [21] [22] [23] . Although the domain was not considered to be relevant by the expert panel, we still recommend being alert for conflicts of interests by all stakeholders involved in the guideline-development process.
The formulation of recommendations, in particular when the evidence is inconsistent, scarce, or lacking, is complex and value-loaded. The composition of guideline-development group as well as group dynamics can influence this process [2, 24] . As a consequence, it may be difficult to describe arguments beyond the evidence in a transparent way. Attempts to design a uniform system for grading the strength of recommendations should balance the need for simplicity with the need for full and transparent consideration of all relevant issues [25, 26] .
Conclusions
This is the first formal consensus approach to explore other considerations apart from the scientific evidence relevant in formulating recommendations in clinical guidelines. The final checklist can be used during the process of guideline development and offers guideline developers the opportunity of systematically considering many additional items beyond the evidence when formulating recommendations. A systematic approach may also help in grading the strength of the final recommendations. If the list is used in parallel with the AGREE Instrument, it could enhance the quality and transparency of the guideline [18] . We encourage further testing of the validity and usefulness of this list for guideline developers in practice. ..................................................................................................................................................................................................................... 
Clinical relevance 1
The sizes of patient populations to which the intervention will apply 20 2.4 (0.9) 85% 2
The magnitude of the effectiveness of an intervention compared with no intervention 20 3.6 (0.5) 85% 3
The consistency of results across different studies 20 3.4 (1.1) 80% 4
The benefit of the intervention compared with another intervention or other interventions 20 3.5 (1.0) 90% 5
The generalizability, taking into account the demographic characteristics of the study population 19 The mean (M), standard deviation (SD), and domain score are given for each item. 
Availability of resources 18
The resources are available in the Netherlands for the organization, the professional and the patient
